Salvianolic acid B noncovalently interacts with disordered c-Myc: a computational and spectroscopic-based study

Future Med Chem. 2021 Aug;13(16):1341-1352. doi: 10.4155/fmc-2021-0087. Epub 2021 Jun 11.

Abstract

Aims: c-Myc, along with its partner MAX, regulates the expression of several genes, leading to an oncogenic phenotype. The MAX interacting interface of c-Myc is disordered and uncharacterized for small molecule binding. Salvianolic acid B possesses numerous therapeutic properties, including anticancer activity. The current study was designed to elucidate the interaction of the Sal_Ac_B with the disordered bHLH domain of c-Myc using computational and biophysical techniques. Materials & methods: The binding of Sal_Ac_B with Myc was studied using computational and biophysical techniques, including molecular docking and simulation, fluorescence lifetime, circular dichroism and anisotropy. Results & conclusions: The study demonstrated a high binding potential of Sal_Ac_B against the disordered Myc peptide. The binding of the compounds leads to an overall conformational change in Myc. Moreover, an extensive simulation study showed a stable Sal_Ac_B/Myc binding.

Keywords: MD simulations; c-Myc/MAX heterodimer; fluorescence lifetime; salvianolic Acid B; time-resolved anisotropy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anisotropy
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Benzofurans / chemistry
  • Benzofurans / pharmacology*
  • Binding Sites / drug effects
  • Circular Dichroism
  • Humans
  • Models, Molecular
  • Molecular Conformation
  • Proto-Oncogene Proteins c-myc / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-myc / chemistry
  • Spectrometry, Fluorescence

Substances

  • Antineoplastic Agents
  • Benzofurans
  • Proto-Oncogene Proteins c-myc
  • salvianolic acid B